Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8: early-phase trial registry
3 of 9 indexed Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8: 9 US clinical trials tracked, 3 recruiting.
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition clinical-stage-iva-gastroesophageal-junction-adenocarcinoma-ajcc-v8
OPEN 3 | RECR 33% | LATE 0 | EARLY 9 | RANK #1916 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 is recruiting below its size-band peers.
3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 research.
M.D. Anderson Cancer Center accounts for 5 of 9 trials (55.6%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 27 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Academic and Community Cancer Research United
NCT04660760
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
NCT04771520
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
NCT05041153
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
NCT05836584
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
M.D. Anderson Cancer Center
NCT03776487
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
NCT04220827
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
NCT04522336
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
NCT04460937
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
NCT04929392
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 page
9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 condition card totals 9 registered trials; most-linked intervention Paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.